Drugs / GenSci143
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07252414 | Dec 2025 → Oct 2028 expected | cancer | Changchun GeneScience Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2024-11-11 | Changchun GeneScience Pharmaceutical Co., Ltd. | Results World ADC San Diego 2024: GenSci showcases two innovative pipeline programs genscigroup.com ↗
In human CDX models of PCa in mice, GenSci143 effectively induced tumor regression across different expression levels of B7-H3 and PSMA and demonstrated superior anti-tumor efficacy versus the DS-7300 and ARX517 analogs. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2024-11-11 | Changchun GeneScience Pharmaceutical Co., Ltd. | World ADC San Diego 2024: GenSci showcases two innovative pipeline programs genscigroup.com ↗ |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GenSci143 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07252414 ↗ |